The T790M mutation was not detected at 1D, the time point of SCLC transformation following osimertinib treatment, but BRAF rearrangement CTNNB1 substitution, KEL splice site mutation, and NF1 frameshift mutations were found. Here, KEL is linked to small cell lung carcinoma.